Navigation Links
Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS)

JERUSALEM, & LUND, Sweden--(BUSINESS WIRE)--May 1, 2007 - Teva Pharmaceutical Industries Ltd. and Active Biotech AB today announced that data from a 36-week, randomized, double-blind, placebo-controlled Phase IIb study demonstrated that an oral 0.6 mg dose of laquinimod given daily significantly reduced magnetic resonance imaging (MRI) disease activity by 38 percent in RRMS patients and was well tolerated. In addition, there was a favorable trend towards reducing annual relapse rates, the number of relapse-free patients and time to first relapse compared with placebo. Treatment with a 0.3 mg dose showed no statistical significant difference compared with placebo.

These data were presented at the 59th Annual Meeting of the American Academy of Neurology (AAN) in Boston, MA, April 28 - May 5, 2007.

"Current RRMS options are effective for the treatment of the disease, but an oral therapy such as laquinimod would represent a milestone for patients as it would provide them with a completely unique, non-invasive method of drug delivery," said Giancarlo Comi, M.D., Director of Department of Neurology and Institute of Experimental Neurology, Universita Vita-Salute, San Raffaele, Milan, Italy. "Preliminary studies have already demonstrated the positive effect of laquinimod versus placebo, but these new data confirmed that a higher dose was even more effective and remained well tolerated."

The 36-week study evaluated the effect of oral daily 0.3 and 0.6 mg doses of laquinimod on MRI-monitored disease activity in patients with RRMS. The majority of the patients who participated in the study continued treatment with laquinimod in an ongoing, blinded 9 month extension study. This extension study is followed by an open label study where patients will receive 0.6 mg laquinimod for an additional 24 months.

"The results of this study, which once again demonstrate the efficacy and tolerability of once-dai
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
(Date:7/10/2014)... 10, 2014 Decision Resources Group finds that ... U.S. Food and Drug Administration,s (FDA) approval of Vifor ... which was approved by the FDA in November 2013 ... (CKD) patients on dialysis. Other key findings ... Q2 2014 : ...
(Date:1/15/2014)... Most osteoporosis patients want a choice in the ... sponsored by Mission Pharmacal Company. The survey, conducted by ... support community, revealed that 74 percent of osteoporosis patients ... form other than a pill or a tablet. ...
(Date:1/15/2014)... 15, 2014 AARP Foundation today announced it has established ... from the severe cold weather that has gripped much of ... those in need; so to support these emergency relief efforts ... $250,000, which could mean up to $500,000 in aid. The ...
Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
... Medical Group,s (FMG) subsidiaries, VasoStar Inc., Mentor, Ohio  today ... Frontier grant to further develop and commercialize a novel ... Occlusions (CTOs), in lieu of invasive open heart surgery ... VasoStar,s primary clinical development partner is the Cleveland ...
... July 20, 2011 Advanced Health Media (AHM), the ... solutions for the pharmaceutical industry, has named James Burgess ... assumes responsibility from Jeff Brady who has served as ... as its President for 9 years. James brings over ...
Cached Medicine Technology:Frantz Medical Group Subsidiary, VasoStar, Awarded $1 Million Research Grant 2Frantz Medical Group Subsidiary, VasoStar, Awarded $1 Million Research Grant 3Advanced Health Media Announces New CEO 2
(Date:7/11/2014)... According to new report "C4ISR Market ... to register a CAGR of 2.28% to reach ... data tables and 76 figures spread through 185 ... http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , Early buyers will receive 10% ... The report provides market analysis of the global ...
(Date:7/11/2014)... 11, 2014 As transvaginal mesh ... Johnson & Johnson’s Ethicon Inc. unit continue to ... that the Texas Attorney General’s Office has acknowledged ... surgical mesh products used to treat pelvic organ ... report from kens5.com, the probe began nearly two ...
(Date:7/11/2014)... -- Reducing the number of deer in an area ... other tick-borne infections among people, new research indicates. ... to reduce human interactions with deer, infected nymphal ticks ... wrote. White-tailed deer are the primary host for ... The study included nearly all the permanent residents ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, ... who was thought to be cured by immediate and aggressive ... of the AIDS-causing virus in her bloodstream, disappointed federal officials ... old, had remained virus-free even though she stopped taking HIV ... her remission would open the door to a functional cure ...
(Date:7/11/2014)... 11, 2014 Microbiology testing is a ... diagnostics industry, which is expected to pose the biggest ... sector owes its growth to the ongoing spread of ... worldwide and a major factor leading to the upsurge ... bio-terrorism, and a broader availability of immunosuppressants, among others. ...
Breaking Medicine News(10 mins):Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 3Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3
... , MONDAY, Dec. 19 (HealthDay News) -- A new analysis on ... cuts fracture risk in older adults, but only when taken with ... D -- present in a small number of foods and produced ... Preventive Services Task Force (USPSTF) also indicates that it,s too soon ...
... jeopardize access to medical care for many millions ... the American College of Physicians (ACP) in a ... Senate leadership. ACP is the largest physician ... United States, representing 132,000 internal medicine specialist physicians ...
... have discovered a missing link between the body,s biological ... help avoid the serious side effects of drugs used ... paper published last week in Nature, scientists at the ... that control the body,s biological rhythms, known as cryptochromes, ...
... , MONDAY, Dec. 19 (HealthDay News) -- Blood ... for heart disease and stroke, a new study suggests. ... pressure readings were tracked for an average of 14 years. ... normal levels by age 55 had the lowest lifetime risk ...
... mice suggest that blocking the production of small molecules ... may represent a novel strategy for treating cancer by ... research is the first to show that EETs work ... protein known to induce blood vessel growth. Together, EETs ...
... naturally in the body from a major component of ... are currently in clinical trials for the treatment of ... led by Dipak Panigrahy and Mark Kieran, at ... Institute for Systems Biology, Seattle; and Darryl Zeldin, at ...
Cached Medicine News:Health News:Vitamin D Helps Bone Health Only With Calcium: Report 2Health News:Vitamin D Helps Bone Health Only With Calcium: Report 3Health News:Congress' 'disarray' makes it 'likely' that 27 percent Medicare cut will go in effect 2Health News:Salk discovery may lead to safer treatments for asthma, allergies and arthritis 2Health News:Salk discovery may lead to safer treatments for asthma, allergies and arthritis 3Health News:Blood Pressure Control in Middle Age Can Lower Lifetime Heart Risk 2Health News:NIH scientists find a potential new avenue for cancer therapies 2Health News:NIH scientists find a potential new avenue for cancer therapies 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: